Cellectis SA at Barclays Global Healthcare Conference Transcript
Good morning, everyone. Welcome to Barclays Global Healthcare Conference. It is my great pleasure to introduce our next presenting company, Cellectis. With us today, we have Andre Choulika, Chief Executive Officer; and also Arthur Stril, our Chief Business Officer. Arthur, maybe I will hand over to you to give a intro for the company.
Thank you, Gena, and good morning, everyone. I will just do a brief like 5 minutes overview of where we are and what's to be expected for this year, in particular, to let ample time for Gena to ask questions.
So we're primarily, as you know, a gene editing company, with a strong focus on allogeneic CAR T cells. We have currently 3 ongoing clinical trials in hematological malignancies with more than 30 patients dosed in our wholly-controlled programs as well as 5 additional trials with our licensed partners, Servier, Allogene, and very recently, Iovance, with more than 140 patients dosed.
We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
